Current Strategies for Brain Drug Delivery
By Xiaowei Dong. Theranostics, 2018
778 citations recorded by the source corpus.
The blood-brain barrier (BBB) has been a great hurdle for brain drug delivery. The BBB in healthy brain is a diffusion barrier essential for protecting normal brain function by impeding most compounds from transiting from the blood to the brain; only small molecules can cross the BBB. Under certain pathological conditions of diseases such as stroke, diabetes, seizures, multiple sclerosis, Parkinson's disease and Alzheimer disease, the BBB is disrupted. The objective of this review is to provide a broad overview on current strategies for brain drug delivery and related subjects from the past five years. It is hoped that this review could inspire readers to discover possible approaches to deliver drugs into the brain. After an initial overview of the BBB structure and function in both healthy and pathological conditions, this review re-visits, according to recent publications, some questions that are controversial, such as whether nanoparticles by themselves could cross the BBB and whether drugs are specifically transferred to the brain by actively targeted nanoparticles. Current non-nanoparticle strategies are also reviewed, such as delivery of drugs through the permeable BBB under pathological conditions and using non-invasive techniques to enhance brain drug uptake. Finally, one particular area that is often neglected in brain drug delivery is the influence of aging on the BBB, which is captured in this review based on the limited studies in the literature.
Subfields: Biomaterials, Molecular Biology, Neurology
View Paper: https://www.semanticscholar.org/paper/766fa32241ebebae4cad0b363a0d2d7f0189fde8
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
- R. Trivedi
- R. Lamptey
- Jagdish Singh
- J. Hanna
- G. Hossain
- Bivek Chaulagain
- Avinash Gothwal
- J. Kocerha
Citations in the corpus
- A Review of the Common Neurodegenerative Disorders: Current Therapeutic Approaches and the Potential Role of Nanotherapeutics (2022, background): “The efficacy of systematically administered drugs is mostly determined by their pharmacokinetic characteristics [83].”
- The Potential for microRNA Therapeutics and Clinical Research (2019, background): “Modified micelle, liposome, nanoparticle, intranasal, and other delivery methods have all been tested for blood-brain barrier crossing and delivery with varying levels of success (Garg et al., 2015; Dong, 2018).”